Compare OTTR & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OTTR | ACAD |
|---|---|---|
| Founded | 1907 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.8B |
| IPO Year | 2009 | 2000 |
| Metric | OTTR | ACAD |
|---|---|---|
| Price | $89.04 | $22.55 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 22 |
| Target Price | N/A | ★ $30.55 |
| AVG Volume (30 Days) | 210.1K | ★ 1.3M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.62% | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | ★ 6.55 | 2.30 |
| Revenue | ★ $1,299,640,000.00 | $726,437,000.00 |
| Revenue This Year | $1.99 | $18.80 |
| Revenue Next Year | $3.83 | $11.70 |
| P/E Ratio | $13.45 | ★ $9.64 |
| Revenue Growth | N/A | ★ 40.45 |
| 52 Week Low | $73.74 | $14.45 |
| 52 Week High | $92.24 | $28.35 |
| Indicator | OTTR | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 53.63 | 54.22 |
| Support Level | $84.38 | $20.80 |
| Resistance Level | $89.87 | $22.97 |
| Average True Range (ATR) | 1.86 | 0.61 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 53.69 | 86.89 |
Otter Tail Corp is a U.S. energy company that operates in the electric (produces and sells electricity), manufacturing (fabricates metal components), and plastics segments (pipes for water uses). The company conducts its operations and acquires the majority of its revenue in the U.S. in the states of Minnesota, South Dakota, and North Dakota. The majority of the company's revenue is derived from the Electric segment and commercial customers, although it generates revenue from residential and industrial customers, as well.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.